Why Pharma Companies Are Investing in Next-Generation Radiopharmaceuticals in 2026

Radiopharmaceuticals are gaining strategic attention as pharmaceutical companies invest in targeted cancer treatments, radioisotope production and specialized manufacturing. These therapies use radioactive materials to detect or treat disease, with some designed to deliver radiation directly to cancer cells.

The latest funding rounds and acquisition agreements show that companies are investing beyond drug discovery. They are also building the manufacturing capacity and supply networks needed to advance clinical programs and support future commercial launches.

Download Sample Report: https://www.towardshealthcare.com/download-sample/5552 

5 Major Radiopharmaceutical Investments to Watch in 2026

These figures represent different transaction types, including equity financing, acquisition consideration and a financing package that includes loans and public subsidies.

What Is Driving These Investments?

1. AdvanCell: $315 Million for Targeted Alpha Therapy

AdvanCell closed a $315 million Series D financing in July 2026. The funding will support ADVC001, its lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer, alongside clinical development and manufacturing infrastructure.

The investment highlights how targeted alpha therapies are attracting capital for both clinical progress and future production capacity.

2. Ratio Therapeutics: $70 Million for Pipeline Development

Ratio Therapeutics closed a $70 million Series C financing in July 2026, bringing its total capital raised to more than $240 million. Investors included Bristol Myers Squibb and Eli Lilly, alongside other backers.

The proceeds will support the clinical development of its lead radiotherapeutic candidate, [Ac-225]RTX-2358, and advancement of another candidate into clinical development.

3. GE HealthCare and SOFIE Biosciences: $945 Million Acquisition

GE HealthCare announced an agreement in October 2026 to acquire SOFIE Biosciences for $945 million in cash. SOFIE's U.S. network includes 15 contract manufacturing sites and 21 cyclotrons.

The deal is intended to strengthen access to PET radiopharmaceuticals and expand GE HealthCare's position in the supply chain. The acquisition remains subject to closing conditions and regulatory approvals.

4. Telix and ITM: $1.65 Billion Upfront

Telix announced a strategic agreement in September 2026 to acquire ITM Isotope Technologies Munich. The transaction includes $1.65 billion in upfront consideration and up to $700 million in additional payments tied to regulatory and sales milestones.

The proposed combination brings together radiopharmaceutical development, isotope production and a complementary therapeutic pipeline. It illustrates the strategic value of connecting drug development with reliable isotope supply and manufacturing.

5. Protherium: €15 Million for European Manufacturing

Protherium closed a €15 million financing round in September 2026 to develop its radiopharmaceutical manufacturing network. The financing includes equity, bank loans and public subsidies.

The company plans to develop its Nancy site in France and expand into Belgium and Germany. Its investment reflects the importance of production infrastructure as more radiopharmaceutical candidates progress toward later-stage development and commercialization..

Where Are the Next Business Opportunities?

The five developments point to several areas for strategic evaluation:

• Pipeline intelligence: Compare clinical stages, therapeutic targets, trial progress and competing drug candidates.

• Radioisotope supply: Assess isotope availability, supplier concentration and regional supply-chain risks.

• Manufacturing capacity: Track cyclotrons, GMP facilities, CDMOs and planned capacity expansions.

• Competitive benchmarking: Identify companies gaining funding, entering partnerships or expanding into new geographies.

• Buyer identification: Map pharmaceutical companies, biotechnology firms, manufacturers and investors with relevant business needs.

How Towards Healthcare Supports Strategic Decisions

Towards Healthcare Research & Consulting helps pharmaceutical and biotechnology businesses evaluate competitive positioning through pipeline intelligence, competitive quadrants, complete master datasets, buyer identification and customized dashboards.

These resources can help decision-makers track company developments, assess competitors, identify partnership prospects and evaluate emerging opportunities across radiopharmaceutical pipelines and manufacturing.

About Us

Healthcare WebWire is part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium